Business
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind Technology CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc.
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nCompany Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind Technology\n\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that the U.S. Patent and Trademark Office has issued a notice of allowance to University of Iowa Research Foundation (\"UIRF\") for U.S. Application No. 17,857,723 titled Compositions and Methods for Detecting Predisposition to Cardiovascular Disease, which is exclusively licensed to the Company from UIRF, and that was co-invented by Cardio Diagnostics' founders, Meesha Dogan, Ph.D., and Robert Philibert, MD Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively. This is the second U.S. patent being issued in this patent family. Patents in this patent family have also been issued in the European Union, China, India, and Australia.\n\n\nAmong Escalating CVD Burden, Company Continues to Expand IP Portfolio\n\n\nAccording to the American Heart Association, cardiovascular disease (CVD) claims 2,552 lives daily in the United States, translating to a death every 34 seconds. Heart disease, which includes heart attacks, has been the leading cause of death in the United States for 100 years. On average, a heart attack occurs every 40 seconds in the U.S., with around 605,000 new and 200,000 recurrent heart attacks reported annually.\n\n\nUnfortunately, an estimated 170,000 of these heart attacks are silent, occurring without significant symptoms. This can mean that many Americans with a silent event are not being identified as at high risk early enough, nor are they being identified after the event. These figures underscore the critical health burden posed by CVD and heart disease in the U.S., highlighting the urgent need for enhanced prevention, detection, management, and treatment strategies. The Company continues to expand the IP portfolio protections associated with its Integrated Epigenetic-Genetic Engine technology, which lies at the heart of its solutions to this growing burden. The Company's IP portfolio also encompasses its clinical blood tests, Epi+Gen CHDTM and PrecisionCHDTM, and software solutions, HeartRiskTM and CardioInnovate360TM.\n\n\nMeesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics, stated, \"The issuance of our latest patent helps...